Provided by Tiger Fintech (Singapore) Pte. Ltd.

LAVA Therapeutics N.V.

1.51
-0.0200-1.31%
Post-market: 1.510.00000.00%16:10 EDT
Volume:341.46K
Turnover:520.80K
Market Cap:39.72M
PE:-1.43
High:1.55
Open:1.53
Low:1.50
Close:1.53
52wk High:2.09
52wk Low:0.8502
Shares:26.31M
Float Shares:10.22M
Volume Ratio:2.91
T/O Rate:3.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0538
EPS(LYR):-0.9359
ROE:-90.19%
ROA:-21.30%
PB:1.99
PE(LYR):-1.61

Loading ...

LAVA Therapeutics NV Appoints KPMG as New Auditor, Dismisses PwC Amid Remediated Internal Control Weaknesses

Reuters
·
May 24

LAVA Therapeutics NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 19

LAVA Therapeutics NV expected to post a loss of 31 cents a share - Earnings Preview

Reuters
·
May 16

Press Release: LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

Dow Jones
·
May 14

BRIEF-Lava Therapeutics Granted Full Waiver For RVO Payment Obligation

Reuters
·
Apr 16

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

GlobeNewswire
·
Apr 16

Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues

Simply Wall St.
·
Apr 06

Lava Therapeutics Price Target Maintained With a $1.50/Share by HC Wainwright & Co.

Dow Jones
·
Mar 31

JMP Securities Sticks to Its Hold Rating for LAVA Therapeutics (LVTX)

TIPRANKS
·
Mar 29

LAVA Therapeutics NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 28

BRIEF-LAVA Therapeutics Q4 Basic EPS USD -0.14

Reuters
·
Mar 28

Press Release: LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Dow Jones
·
Mar 28

LAVA Therapeutics NV expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Mar 21

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 20

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 17

LAVA Therapeutics NV expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Mar 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 14

BRIEF-LAVA Therapeutics NV Receives Nasdaq Non-Compliance Notice For Minimum Bid Price

Reuters
·
Mar 01

Lava Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Feb 27

HC Wainwright Downgrades LAVA Therapeutics to Neutral From Buy, Adjusts Price Target to $1.50 From $2

MT Newswires Live
·
Feb 27